AKBA Akebia: Forward P/S Multiple

Akebia Corp (AKBA) - corporate logo

Raw material supply chain disruption risks have created volatility, as demonstrated by the forward EV/Revenue multiple. The current 0.60 figure determines the metric's magnitude, capturing the market's reaction to management's efforts to bring anemia drugs to market. Consequently, Akebia Therapeutics (AKBA) has focused on organic sales growth and distribution, eschewing merger deals.

AKBA akebia.com: Forward P/S Multiple in the range 07/04/2022 - 11/18/2026

Akebia Therapeutics (AKBA) - metric breakdowns and financial figures

- stock price and consensus target price:
Comprehensive company analysis:Akebia Therapeutics Inc AKBA
Product sample of Akebia Corp

Defensive assets are selected based on criteria of low volatility and operational resilience. Akebia Therapeutics (AKBA) meets these requirements by minimizing capital expenditures through the outsourcing of drug production to contract manufacturing organizations. The company's forward P/S ratio compares the current market value of the business with expected revenue. The price action on this chart allows for an assessment of the issuer's valuation adequacy relative to its future cash flows.